BIONICHE LIFE SCIENCES ANNOUNCES TERMS OF $5 MILLION FINANCING & USE OF PROCEEDS
Bioniche Life Sciences Inc. has released the terms of its previously announced overnight marketed public offering with a syndicate of agents led by Dundee Securities Ltd., and including Clarus Securities Inc. and Euro Pacific Canada Inc. In connection with the Offering, Bloom Burton & Co. Inc. has been appointed as a selling group member.
The Offering will consist of 21,800,000 units of the Company (the "Units"), each Unit consisting of one common share (each, a "Share") and one-half of one common share purchase warrant (each, a "Warrant" and together, the "Warrants") at a price per Unit of $0.23 (the "Offering Price") for aggregate gross proceeds of $5,014,000. Each whole Warrant will entitle the holder thereof to acquire one Share of the Company at a price per Share of $0.30 for a period of 60 months following the issuance thereof.
The Company plans to file an amended preliminary prospectus today reflecting the terms herein. The Offering is scheduled to close on or about September 10, 2014. The Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals.
The net proceeds of the Offering will be used by the Company to complete the filing with the United States Food & Drug Administration (FDA) of a Biologics License Application (BLA) for their lead program Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed Bacillus Calmette-Guerin (BCG) therapy, and for working capital and general corporate purposes.